Danish Covid-19 therapy shows promise in phase I trial

Union Therapeutics' study with the drug niclosamide for treating Covid-19 patients with kidney diseases shows promising data in a Danish phase I trial program.

Photo: Union Therapeutics / PR

Biotech company Union Therapeutics is excited about positive preliminary trial data involving the company's niclosamide nasal spray, which it hopes will have an efficient impact on kidney patients with Covid-19.

The phase I trial, which was took place in Denmark and was supported by Innovation Fund Denmark, met its endpoints in terms of safety and avoidance of serious side effects, the company notes in a press announcement.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs